MANGOCEUTICALS, INC.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
MGRX$0.20+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| June 30, 2026 | December 31, 2025 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $228,688 | $1,486,338 |
| Prepaid expenses | 42 | 7,021 |
| Prepaid expenses - related party | - | 120 |
| Deposits | 16,957 | 33,899 |
| Due from related party | - | 20,056 |
| TOTAL CURRENT ASSETS | 245,687 | 1,547,434 |
| NON-CURRENT ASSETS | ||
| Property and equipment, net of accumulated depreciation of $3,770 and $3,268 | 1,292 | 1,794 |
| Right of use - asset | 279,246 | 307,861 |
| Intangible assets - acquired patents and license, net of amortization | 13,646,570 | 14,232,484 |
| TOTAL NON-CURRENT ASSETS | 13,927,108 | 14,542,139 |
| TOTAL ASSETS | $14,172,795 | $16,089,573 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | $889,733 | $416,682 |
| Payroll tax liabilities | 6,634 | 9,421 |
| Deposit/contract liability | 275,000 | - |
| Operating lease liability - current | 28,301 | 307,823 |
| Accrued liabilities - related parties | 6,000 | - |
| Notes payable - related parties | 44,944 | - |
| Other liabilities - patent purchase payable | 147,451 | 156,642 |
| TOTAL CURRENT LIABILITIES | 1,398,063 | 890,568 |
| LONG-TERM LIABILITIES | ||
| Operating lease liability - net of current portion | 250,906 | - |
| TOTAL LONG-TERM LIABILITIES | 250,906 | - |
| TOTAL LIABILITIES | 1,648,969 | 890,568 |
| COMMITMENTS AND CONTINGENCIES (SEE NOTE 7) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Series B Convertible Preferred stock, (par value $0.0001), 6,000 shares authorized, 50 and 50 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | - | - |
| Series C Convertible Preferred stock, (par value $0.0001), 6,250,000 shares authorized, 980,000 and 980,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 98 | 98 |
| Common stock (par value $0.0001), 200,000,000 shares authorized, of which 18,017,421 and 15,888,795 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 1,803 | 1,589 |
| Stock warrants | 324,288 | 324,288 |
| Additional paid in capital | 57,568,236 | 55,524,812 |
| Accumulated deficit | (45,363,283) | (40,647,480) |
| Accumulated other comprehensive loss | (5,198) | (2,760) |
| TOTAL STOCKHOLDERS’ EQUITY | 12,525,944 | 15,200,547 |
| Non-controlling interest | (2,118) | (1,542) |
| TOTAL STOCKHOLDERS’ EQUITY | 12,523,826 | 15,199,005 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $14,172,795 | $16,089,573 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.